- Active not recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)
This study looks at a new medicine called ocrelizumab for children and teenagers aged 10-17 with a type of MS called relapsing-remitting multiple sclerosis (RRMS). It compares ocrelizumab to an existing medicine, fingolimod, to see how safe and effective it is over a period of time.
For: Relapsing-Remitting Multiple SclerosisUnited States · Argentina · Australia - Active not recruitingPHASE3
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
This study looks at how safe and effective two medicines, fingolimod and interferon beta-1a, are for young people aged 10-17 with multiple sclerosis (MS). It compares them to see which works best and is safest.
For: Multiple SclerosisUnited States · Australia · Austria